ReviewAnnals of translational medicine2018
New treatments of multidrug-resistant Gram-negative ventilator-associated pneumonia.
Review in Annals of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Emergence of eravacycline heteroresistance in carbapenem-resistantFrontiers in cellular and infection microbiology · 2024Article
- Comparison of antimicrobial activities and resistance mechanisms of eravacycline and tigecycline against clinicalFrontiers in microbiology · 2024Article
- Acinetobacter Metabolism in Infection and Antimicrobial Resistance.Infection and immunity · 2023Review
- Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives.Biological reviews of the Cambridge Philosophical Society · 2022Review
- Article
- In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan.Microorganisms · 2020Article
- Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: the NEW_SAFE project.BMJ open · 2020Article
- Combined Use of Three Machine Learning Modeling Methods to Develop a Ten-Gene Signature for the Diagnosis of Ventilator-Associated Pneumonia.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- TheAnnals of translational medicine · 2019Article
- Clonal dissemination of KPC-2-producingAnnals of translational medicine · 2019Article
- Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline.Clinical pharmacokinetics · 2019Review
- Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis.Case reports in obstetrics and gynecology · 2019Article
- The "Old" and the "New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How.Frontiers in public health · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ventilator-associated pneumonia (VAP) remains an important clinical problem globally, being associated with significant morbidity and mortality. As management of VAP requires adequate and timely antibiotic administration, global emergence of antimicrobial resistance poses serious challenges over our ability to maintain this axiom. Development of antimicrobials against MDR Gram-negative pathogens has therefore emerged as a priority and some new antibiotics have been marketed or approach late stage of development. The aim of this review is to analyse new therapeutic options from the point view of potential treatment of VAP. Among recently developed antimicrobials presented herein, it is obvious that we will have promising therapeutic options against VAP caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.